Neuraminidase receptor binding variants of human influenza A(H3N2) viruses resulting from substitution of aspartic acid 151 in the catalytic site: a role in virus attachment?
Changes in the receptor binding characteristics of human H3N2 viruses have been evident from changes in the agglutination of different red blood cells (RBCs) and the reduced growth capacity of recently isolated viruses, particularly in embryonated eggs. An additional peculiarity of viruses circulating in 2005 to 2009 has been the poor inhibition of hemagglutination by postinfection ferret antisera for many viruses isolated in MDCK cells, including homologous reference viruses. This was shown not to be due to an antigenic change in hemagglutinin (HA) but was shown to be the result of a mutation in aspartic acid 151 of neuraminidase (NA) to glycine, asparagine, or alanine, which caused an oseltamivir-sensitive agglutination of RBCs. The D151G substitution was shown to cause a change in the specificity of NA such that it acquired the capacity to bind receptors, which were refractory to enzymatic cleavage, without altering its ability to remove receptors for HA. Thus, the inhibition of NA-dependent agglutination by the inclusion of oseltamivir carboxylate in the assay was effective in restoring the anti-HA specificity of the hemagglutination inhibition (HI) assay for monitoring antigenic changes in HA. Since the NA-dependent binding activity did not affect virus neutralization, and virus populations in clinical specimens possessed, at most, low levels of the "151 mutant," the biological significance of this feature of NA in, for example, immune evasion is unclear. It is apparent, however, that an important role of aspartic acid 151 in the activity of NA may be to restrict the specificity of the NA interaction and its receptor-destroying activity to complement that of HA receptor binding.
Lin
Yi Pu
YP
Virology Division, MRC National Institute for Medical Research, The Ridgeway, Mill Hill, London NW7 1AA, United Kingdom. lyipu@nimr.mrc.ac.uk
Gregory
Victoria
V
Collins
Patrick
P
Kloess
Johannes
J
Wharton
Stephen
S
Cattle
Nicholas
N
Lackenby
Angie
A
Daniels
Rodney
R
Hay
Alan
A
D019943:Amino Acid Substitution / Q000235:genetics; D000818:Animals; D000998:Antiviral Agents / Q000378:metabolism; D001224:Aspartic Acid / Q000235:genetics*; D020134:Catalytic Domain; D002460:Cell Line; D004285:Dogs; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D053122:Influenza A Virus, H3N2 Subtype / Q000235:genetics / Q000302:isolation & purification / Q000502:physiology*; D007251:Influenza, Human / Q000821:virology; D020125:Mutation, Missense; D009439:Neuraminidase / Q000235:genetics* / Q000378:metabolism*; D009500:Neutralization Tests; D053139:Oseltamivir / Q000378:metabolism; D011485:Protein Binding; D011991:Receptors, Virus / Q000378:metabolism*; D014764:Viral Proteins / Q000235:genetics* / Q000378:metabolism*; D053585:Virus Attachment
D000998:Antiviral Agents; D011991:Receptors, Virus; D014764:Viral Proteins; D053139:Oseltamivir; D001224:Aspartic Acid; C487630:NA protein, influenza A virus; D009439:Neuraminidase
Virology. 1984 Sep;137(2):314-23
6485252
Virology. 1991 Aug;183(2):496-504
1853557
Eur J Biochem. 1992 Jul 1;207(1):335-43
1628657
J Virol. 2005 Jun;79(11):6763-71
15890915
Antimicrob Agents Chemother. 2003 Jul;47(7):2264-72
12821478
Proteins. 1992 Nov;14(3):327-32
1438172
Antimicrob Agents Chemother. 2008 Sep;52(9):3284-92
18625765
Nature. 2006 Sep 7;443(7107):45-9
16915235
Virol J. 2006 Aug 31;3:63
16945126
Virology. 2001 Oct 10;289(1):74-85
11601919
Vaccine. 2010 Feb 3;28(5):1156-67
20004635
Arch Virol. 2009;154(6):945-57
19458903
J Virol. 1986 Feb;57(2):623-8
2418215
Nature. 2008 Jun 26;453(7199):1258-61
18480754
Biochemistry. 1994 Jul 12;33(27):8172-9
8031750
J Virol. 2009 Oct;83(20):10366-73
19641000
J Virol. 1995 Feb;69(2):1099-106
7815489
Wkly Epidemiol Rec. 2009 Oct 9;84(41):421-31
19817019
Proc Natl Acad Sci U S A. 2000 May 23;97(11):6108-13
10801978
Antiviral Res. 2010 Feb;85(2):381-8
19917319
EMBO J. 1987 May;6(5):1459-65
3608984
J Virol. 1989 Mar;63(3):1239-46
2915381
J Infect Dis. 1979 Dec;140(6):844-50
396336
Virology. 2005 Aug 15;339(1):12-20
15950996
Nature. 1983 May 5-11;303(5912):41-4
6188957
Proteins. 1989;6(4):341-56
2482974
Science. 2009 Oct 30;326(5953):734-6
19900932
Virology. 1974 Oct;61(2):397-410
4472498
Virology. 1984 Oct 15;138(1):174-7
6208680
Virus Res. 2004 Jul;103(1-2):47-52
15163487
Virol J. 2007 May 09;4:42
17490484
Virology. 2003 Sep 1;313(2):473-80
12954214
Proc Natl Acad Sci U S A. 1997 Oct 28;94(22):11808-12
9342319
J Virol. 1997 Sep;71(9):6706-13
9261394
Rev Med Virol. 2002 May-Jun;12(3):159-66
11987141
Virology. 2000 Dec 20;278(2):587-96
11118381
J Virol. 1987 Sep;61(9):2910-6
3612957
J Virol. 2000 Jul;74(13):6015-20
10846083
J Virol. 2004 Nov;78(22):12665-7
15507653
J Virol. 2003 Aug;77(15):8418-25
12857911
Virology. 1998 Feb 1;241(1):101-11
9454721
Annu Rev Biochem. 2000;69:531-69
10966468
Eur J Biochem. 1998 Dec 1;258(2):320-31
9874196
Nat Struct Biol. 1999 Jun;6(6):530-4
10360354